Those SA BASSTURDS are either overrun with comments or will not put up mine to AH, which was just asking how does he know partners rejected amrn? or that the scrip count is pitiful? we have to have a base to know whats good and whats not on scrips and thats why I had asked monday about Lovaza scrip numbers when it was released to compare. Also, how in the h3ll does someone like AH get to spout off with this drivel and it be published by SA then he comes on Yahoo and posts this warning.....warning warning warning, will robinson....what rubbish, his clsn call speaks volumns and so does his lack of any DD in this so called article on amrn.
AH rides again. Bwahahaha! Don't waste your time on the article. It's the same old hatchet job he's been doing all along. Instead, just for laughs, read some of his oldies but goodies concerning CLSN. You'll bust a gut! 8)
Sentiment: Strong Buy
Since your "article", if that's what you call it, came out, the pps has actually gone up and closed higher. So your feeble attempt at whatever it is you tried, didn't work.
I actually stopped reading that useless blog once I got to the part you called vascepa a "drug".
Even AF writes better bad articles
bla bla bla who cares? AMRN has been falling on its back side and I've called it correctly every drop of the way.
I am now warning you for the next drop down will be very severe.
AMRN is a loser stock. Shareholders will continue to lose.
You have been warned.
Alex, Alex, Alex. Your history is suspect.
Perhaps you have been posting under "the principle" or "michelle michelle"?
Not posting about AMRN yet you have "called it correctly". What ID were you using at the time.
Take your new ID somewhere else, a**hole.
Sentiment: Strong Buy
SA SHOULD HAVE SOME SCREENING CRITERIA FOR THE COMPETENCY OF CONTRIBUTORS. ALEX HAS VERY LITTLE. HERE IS A COPY AND PASTE OF A PART OF THE FOOL'S SA ARTICLE PUMPING CLSN.
Amarin Corporation (AMRN) has too many concerns, risks, uncertainities, disappointments, a poor balance sheet, and a bloated market cap. Why even touch it when there are better opportunities out there with less risk? Why not sell shares of AMRN (if you own them) and buy an undervalued winner with a bright future and a promising drug that with similar (or bigger) market size but at nearly 1/6th the market cap?
Forget AMRN. Buy Celsion Corporation (CLSN) for a bigger score. CLSN is an oncology drug development company that engages in the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company develops ThermoDox, a liposomal encapsulation of doxorubicin, which is under Phase III clinical trial for primary liver cancer, under phase II clinical trial for colorectal liver metastasis, and under phase II clinical trial for treatment of recurrent chest wall breast cancer.
Six reasons to go long CLSN instead of AMRN:
(1) AMRN is planning to launch its key drug Vascepa in Q1 2013. Although AMRN's market size isn't known yet, Vascepa's main competitor is a drug called Lovaza by GlaxoSmithKline (GSK). According to AMRN's 10K, the market size for Lovaza is $900 million in the US and $1.3 billion worldwide. This suggests the market for AMRN's Vascepa isn't very large. For example, if one took a ridiculously optimistic scenario and assumed AMRN would steal 80% of GSK's market share, the market size would at best be roughly the same size (of at least $1 billion) of CLSN's ThermoDox drug.
(2) Despite the fact that the potential market size for both companies is similar (at best), their respective market caps are light years apart. AMRN trades for around a $1.5 billion market cap while CLSN trades for a far more humble $250 million. To put it in perspective, with CLSN trading at $7 and change, if its market...
hahaha are you serious? This is the worst written article I have ever read. Your track history with CLSN also speaks for itself.
If this is your day job, I'd be looking for a new line of work...